Cloning and characterization of CYP51 from Mycobacterium avium

American Journal of Respiratory Cell and Molecular Biology

Volumn 35, Issue 2, 2006, Pages 236-242

  Pietila, Michael P ^b   Vohra, Pawan K ^b   Sanyal, Bharati ^b   Wengenack, Nancy L ^b   Raghavakaimal, Sreekumar ^b   Thomas Jr , Charles F ^a  

^a Mayo Clinic   (United States)

^b NONE

Author keywords

Azoles; CYP51; ERG11; Lanosterol

Indexed keywords

ANTIMYCOBACTERIAL AGENT; ECONAZOLE; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; LANOSTEROL; MACROLIDE; METHYL GROUP; OBTUSIFOLIOL; PYRROLE DERIVATIVE; STEROL; STEROL 14ALPHA DEMETHYLASE; UNCLASSIFIED DRUG; VORICONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; CATALYSIS; CELL DEATH; CELL MEMBRANE; CHRONIC LUNG DISEASE; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DRUG TARGETING; ELECTRON SPIN RESONANCE; ENZYME ANALYSIS; ENZYME INHIBITION; GROWTH INHIBITION; IMMUNOCOMPETENCE; METHYLATION; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR CLONING; MYCOBACTERIUM AVIUM; MYCOBACTERIUM INTRACELLULARE AVIUM; NONHUMAN; PROTEIN FUNCTION; RELAPSE; STEROL METABOLISM;

ANTI-INFECTIVE AGENTS; ANTIFUNGAL AGENTS; AZOLES; CATALYSIS; CLONING, MOLECULAR; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MICROBIAL; ELECTRON SPIN RESONANCE SPECTROSCOPY; ENZYME INHIBITORS; MACROLIDES; MASS SPECTROMETRY; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM AVIUM; OXIDOREDUCTASES; RECOMBINANT PROTEINS;

ANIMALIA; FUNGI; MYCOBACTERIUM AVIUM; MYCOBACTERIUM AVIUM COMPLEX (MAC);

EID: 33746784276     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2005-0398OC     Document Type: Article

References (42)

1. American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association. Am J Respir Crit Care Med 1997;156(Suppl. 2 pt 2):S1-S25.
2. Prince DS, Peterson DD, Steiner RM, Gottlieb JE, Scott R, Israel HL, Figueroa WG, Fish JE. Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med 1989;321:863-868.
3. Aksamit TR. Mycobacterium avium complex pulmonary disease in patients with pre-existing lung disease. Clin Chest Med 2002;23:643-653.
4. Swensen SJ, Hartman TE, Williams DE. Computed tomographic diagnosis of Mycobacterium avium-intracellulare complex in patients with bronchiectasis. Chest 1994;105:49-52.
5. Field SK, Fisher D, Cowie RL. Mycobacterium avium complex pulmonary disease in patients without HIV infection. Chest 2004;126:566-581.
6. Karakousis PC, Moore RD, Chaisson RE. Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy. Lancet Infect Dis 2004;4:557-565.
7. Horsburgh CR Jr, Selik RM. The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immunodeficiency syndrome (AIDS). Am Rev Respir Dis 1989;139:4-7.
8. Kobashi Y, Matsushima T. Clinical analysis of pulmonary Mycobacterium avium complex disease in association with corticosteroid treatment. J Infect Chemother 2003;9:68-74.
9. Doucette K, Fishman JA. Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients. Clin Infect Dis 2004;38:1428-1439.
10. Aksamit TR. Hot tub lung: infection, inflammation, or both? Semin Respir Infect 2003;18:33-39.
11. Marras TK, Wallace RJ Jr, Koth LL, Stulbarg MS, Cowl CT, Daley CL. Hypersensitivity pneumonitis reaction to Mycobacterium avium in household water. Chest 2005;127:664-671.
12. Reich JM, Johnson RE. Mycobacterium avium complex pulmonary disease: incidence, presentation, and response to therapy in a community setting. Am Rev Respir Dis 1991;143:1381-1385.
13. Goto M, Katsunuma N. Relationship between porphyrin and isoniazid resistance of Mycobacterium avium. Nature 1958;181:916.
14. Heifets LB, Iseman MD, Crowle AJ, Lindholm-Levy PJ. Pyrazinamide is not active in vitro against Mycobacterium avium complex. Am Rev Respir Dis 1986;134:1287-1288.
15. De Wit S, D'Abbraccio M, De Mol P, Clumeck N. Acquired resistance to clarithromycin as combined therapy in Mycobacterium avium intracellulare infection. Lancet 1993;341:53-54.
16. Yoshida Y, Aoyama Y, Noshiro M, Gotoh O. Sterol 14-demethylase P450 (CYP51) provides a breakthrough for the discussion on the evolution of cytochrome P450 gene superfamily. Biochem Biophys Res Commun 2000;273:799-804.
17. Aoyama Y, Noshiro M, Gotoh O, Imaoka S, Funae Y, Kurosawa N, Horiuchi T, Yoshida Y. Sterol 14-demethylase P450 (P45014DM*) is one of the most ancient and conserved P450 species. J Biochem (Tokyo) 1996;119:926-933.
18. Fischer RT, Stam SH, Johnson PR, Ko SS, Magolda RL, Gaylor JL, Trzaskos JM. Mechanistic studies of lanosterol 14 α-methyl demethylase: substrate requirements for the component reactions catalyzed by a single cytochrome P-450 isozyme. J Lipid Res 1989;30:1621-1632.
19. Fischer RT, Trzaskos JM, Magolda RL, Ko SS, Brosz CS, Larsen B. Lanosterol 14 α-methyl demethylase: isolation and characterization of the third metabolically generated oxidative demethylation intermediate. J Biol Chem 1991;266:6124-6132.
20. Bellamine A, Mangla AT, Nes WD, Waterman MR. Characterization and catalytic properties of the sterol 14α-demethylase from Mycobacterium tuberculosis. Proc Natl Acad Sci USA 1999;96:8937-8942.
21. Jackson CJ, Lamb DC, Marczylo TH, Parker JE, Manning NL, Kelly DE, Kelly SL. Conservation and cloning of CYP51: a sterol 14 a-demethylase from Mycobacterium smegmatis. Biochem Biophys Res Commun 2003;301:558-563.
22. Lamb DC, Kelly DE, Manning NJ, Kelly SL. A sterol biosynthetic pathway in Mycobacterium. FEBS Lett 1998;437:142-144.
23. Hitchcock CA, Dickinson K, Brown SB, Evans EG, Adams DJ. Interaction of azole antifungal antibiotics with cytochrome P-450-dependent 14 α-sterol demethylase purified from Candida albicans. Biochem J 1990;266:475-480.
24. Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 1999;12:501-517.
25. Morales IJ, Vohra PK, Puri V, Kottom TJ, Limper AH, Thomas CF Jr. Characterization of a lanosterol 14 α-demethylase from Pneumocystis carinii. Am J Respir Cell Mol Biol 2003;29:232-238.
26. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes. I: evidence for its hemoprotein nature. J Biol Chem 1964;239:2370-2378.
27. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes. II: solubilization, purification, and properties. J Biol Chem 1964;239:2379-2385.
28. Lipscomb JD. Electron paramagnetic resonance detectable states of cytochrome P-450cam. Biochemistry 1980;19:3590-3599.
29. Schaller H. The role of sterols in plant growth and development. Prog Lipid Res 2003;42:163-175.
30. Xu SH, Norton RA, Crumley FG, Nes WD. Comparison of the Chromatographic properties of sterols, select additional steroids and triterpenoids: gravity-flow column liquid chromatography, thin-layer chromatography, gas-liquid chromatography and high-performance liquid chromatography. J Chromatogr 1988;452:377-398.
31. Gomez-Flores R, Gupta S, Tamez-Guerra R, Mehta RT. Determination of MICs for Mycobacterium avium-M. intracellulare complex in liquid medium by a colorimetric method. J Clin Microbiol 1995;33:1842-1846.
32. Clinical Laboratory Standards Institute. Susceptibility testing of Mycobacteria, Nocardiae, and other aerobic actinomycetes; approved standard. Wayne, PA: CLSI; 2003. CLSI document M24-A.
33. Lamb D, Kelly D, Kelly S. Molecular aspects of azole antifungal action and resistance. Drug Resist Updat 1999;2:390-402.
34. Aoyama Y, Yoshida Y. Different substrate specificities of lanosterol 14α-demethylase (P-45014DM) of Saccharomyces cerevisiae and rat liver for 24-methylene-24,25-dihydrolanosterol and 24,25-dihydrolanosterol. Biochem Biophys Res Commun 1991;178:1064-1071.
35. Aoyama Y, Yoshida Y, Sonoda Y, Sato Y. Structural analysis of the interaction between the side-chain of substrates and the active site of lanosterol 14 α-demethylase (P- 450(14)DM) of yeast. Biochim Biophys Acta 1992;1122:251-255.
36. Lamb DC, Kelly DE, Kelly SL. Molecular diversity of sterol 14α-demethylase substrates in plants, fungi and humans. FEBS Lett 1998;425:263-265.
37. Cabello-Hurtado F, Taton M, Forthoffer N, Kahn R, Bak S, Rahier A, Werck-Reichhart D. Optimized expression and catalytic properties of a wheat obtusifoliol 14α-demethylase (CYP51) expressed in yeast: complementation of erg11Delta yeast mutants by plant CYP51. Eur J Biochem 1999;262:435-446.
38. Ji H, Zhang W, Zhang M, Kudo M, Aoyama Y, Yoshida Y, Sheng C, Song Y, Yang S, Zhou Y, et al. Structure-based de novo design, synthesis, and biological evaluation of non-azole inhibitors specific for lanosterol 14α- demethylase of fungi. J Med Chem 2003;46:474-485.
39. Podust LM, Poulos TL, Waterman MR. Crystal structure of cytochrome P450 14α-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors. Proc Natl Acad Sci USA 2001;98:3068-3073.
40. Matsuura K, Yoshioka S, Tosha T, Hori H, Ishimori K, Kitagawa T, Morishima I, Kagawa N, Waterman MR. Structural diversities of active site in clinical azole-bound forms between sterol 14α-demethylases (CYP51s) from human and Mycobacterium tuberculosis. J Biol Chem 2005;280:9088-9096.
41. Jackson CJ, Lamb DC, Kelly DE, Kelly SL. Bactericidal and inhibitory effects of azole antifungal compounds on Mycobacterium smegmatis. FEMS Microbiol Lett 2000;192:159-162.
42. Burguiere A, Hitchen PG, Dover LG, Dell A, Besra GS. Altered expression profile of mycobacterial surface glycopeptidolipids following treatment with the antifungal azole inhibitors econazole and clotrimazole. Microbiol 2005;151:2087-2095.